Skip to main content

ChemoCentryx, Inc. (CCXI)

NASDAQ: CCXI · IEX Real-Time Price · USD
36.28
-2.60 (-6.69%)
At close: Nov 26, 2021 1:00 PM
38.49
2.21 (6.09%)
After-hours:Nov 26, 2021 4:55 PM EST
Market Cap2.54B
Revenue (ttm)34.27M
Net Income (ttm)-121.10M
Shares Out70.03M
EPS (ttm)-1.74
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,115,190
Open39.38
Previous Close38.88
Day's Range35.68 - 38.95
52-Week Range9.53 - 70.29
Beta1.83
AnalystsBuy
Price Target71.38 (+96.7%)
Earnings DateNov 9, 2021

About CCXI

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The...

IndustryBiotechnology
IPO DateFeb 8, 2012
CEOThomas Schall
Employees133
Stock ExchangeNASDAQ
Ticker SymbolCCXI
Full Company Profile

Financial Performance

In 2020, ChemoCentryx's revenue was $64.89 million, an increase of 79.61% compared to the previous year's $36.13 million. Losses were -$55.36 million, -0.24% less than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ChemoCentryx stock is "Buy." The 12-month stock price forecast is 71.38, which is an increase of 96.75% from the latest price.

Price Target
$71.38
(96.75% upside)
Analyst Consensus: Buy

News

ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos

ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.

1 week ago - Zacks Investment Research

Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) ...

SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP)...

2 weeks ago - GlobeNewsWire

ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top

ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.

2 weeks ago - Zacks Investment Research

ChemoCentryx to Participate in Two Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upc...

2 weeks ago - GlobeNewsWire

Big Pharma Is Going Holiday Shopping. Who's Next?

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Other symbols:EPZMHCMMGTA
2 weeks ago - The Motley Fool

ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 30.44% and 20.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Should You Buy ChemoCentryx (CCXI) Ahead of Earnings?

ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

2 weeks ago - Zacks Investment Research

Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight...

SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the Am...

3 weeks ago - GlobeNewsWire

ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close o...

3 weeks ago - GlobeNewsWire

ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 weeks ago - Zacks Investment Research

What's Next For ChemoCentryx Stock After Over A 100% Rise In A Month?

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has skyrocketed with a 104% rise over t...

1 month ago - Forbes

3 Biotech Stocks That Could Rise 90% or More, According to Wall Street

These stocks are expected to put up big gains in a short amount of time.

Other symbols:AXSMOCUL
1 month ago - The Motley Fool

Is It Too Late to Buy ChemoCentryx Stock?

The stock surged after obtaining FDA approval for avacopan.

1 month ago - The Motley Fool

Amber Specialty Pharmacy Selected by ChemoCentryx to Dispense TAVNEOS™ (avacopan), an Adjunctive Treatment for ANCA-A...

OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy announces that it will begin dispensing TAVNEOS™ (avacopan), a first of its kind orally-administered selective complement 5a receptor inhibitor, as...

1 month ago - Business Wire

2 Super-Charged Growth Stocks to Buy Now

These two small drugmakers are poised for a long-winded growth spurt.

Other symbols:BCRX
1 month ago - The Motley Fool

BZ Chart Of The Day: ChemoCentryx

There's an old saying on Wall Street that "gaps refill." It's true and it may be about to happen to shares of ChemoCentryx, Inc. (NASDAQ:CCXI).

1 month ago - Benzinga

ChemoCentryx Appoints Rita I. Jain, M.D.

Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product

1 month ago - GlobeNewsWire

Why ChemoCentryx Stock Skyrocketed Today

Investors are excited about the biotech's game-changing new drug.

1 month ago - The Motley Fool

Should you buy ChemoCentryx stock as shares spike 70% on avacopan approval?

On Friday, ChemoCentryx Inc. (NASDAQ:CCXI) shares spiked nearly 70% after announcing the Food and Drug Administration (FDA) had approved avacopan for the treatment of ANCA vasculitis. Avacopan is an ora...

1 month ago - Invezz

ChemoCentryx (CCXI) Tavneos Gets FDA Nod for ANCA Vasculitis

The FDA approves ChemoCentryx's (CCXI) lead drug Tavneos to treat ANCA-associated vasculitis. It is the company's first drug to get FDA approval.

1 month ago - Zacks Investment Research

ChemoCentryx, Allogene Show the Risks and Rewards of Nasdaq Biotech Stocks

The broader market was mixed on Friday.

1 month ago - The Motley Fool

CCXI Stock: The Big FDA News That Has ChemoCentryx Shares Skyrocketing 60%

CCXI stock is making its investors very happy this morning with some huge gains. It's receiving FDA approval for a rare disease treatment.

1 month ago - InvestorPlace

Here's why ChemoCentryx is up 50% on Friday morning

ChemoCentryx Inc (NASDAQ: CCXI) shareholders had every reason to be happy about on Friday morning. The shares of the group traded higher on Friday morning, thanks to the announcement made by the group.

1 month ago - Invezz

ChemoCentryx (CCXI) Soars 5.4%: Is Further Upside Left in the Stock?

ChemoCentryx (CCXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength...

1 month ago - Zacks Investment Research

Why Did ChemoCentryx Shares Soar 70% On Friday Premarket?

The FDA has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis or ANC...

1 month ago - Benzinga